

CITATION REPORT

List of articles citing

RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases

DOI: 10.2119/2007-00087.koyama
Molecular Medicine, 2007, 13, 625-35.

Source: <https://exaly.com/paper-pdf/42507134/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
131	Raman spectroscopy of advanced glycation end products (AGEs), possible markers for progressive retinal dysfunction. 2008 , 39, 1635-1642		24
130	The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease. 2008 , 41, 981-5		34
129	Lipid homeostasis in macrophages - implications for atherosclerosis. 2008 , 160, 93-125		54
128	Blockade of receptor for advanced glycation end product attenuates pulmonary reperfusion injury in mice. 2008 , 136, 1576-85		42
127	Reviews of Physiology Biochemistry and Pharmacology. 2008 ,		
126	Bioactive peptides control receptor for advanced glycated end product-induced elevation of kidney insulin receptor substrate 2 and reduce albuminuria in diabetic mice. 2008 , 28, 890-9		7
125	Identification, classification, and expression of RAGE gene splice variants. 2008 , 22, 1572-80		278
124	Levels of Soluble Receptor for Advanced Glycation End Products in Acute Ischemic Stroke without a Source of Cardioembolism. 2009 , 5, 126-32		18
123	Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. 2009 , 182, 5778-88		83
122	Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. 2009 , 32, 2263-8		72
121	Soluble forms of RAGE in human diseases: clinical and therapeutical implications. <i>Current Medicinal Chemistry</i> , 2009 , 16, 940-52	4.3	140
120	Regulated cell death pathways: new twists in modulation of BCL2 family function. 2009 , 8, 1421-9		75
119	RAGE gene polymorphisms are associated with circulating levels of endogenous secretory RAGE but not with coronary artery disease in Chinese patients with type 2 diabetes mellitus. 2009 , 40, 393-8		32
118	Human S100A12: a novel key player in inflammation?. 2009 , 36, 381-9		124
117	Soluble forms of RAGE in internal medicine. 2009 , 4, 389-401		143
116	Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. 2009 , 11, R39		80
115	The role of N-ethylmaleimide-sensitive amine oxidase in the arterial wall. 2009 , 3, 141		4

114	Effects of long-term calorie restriction and endurance exercise on glucose tolerance, insulin action, and adipokine production. 2010 , 32, 97-108	126
113	Microglia activation and anti-inflammatory regulation in Alzheimer's disease. 2010 , 41, 115-28	130
112	High-mobility group box protein 1 and its signalling receptors in human preterm and term cervix. 2010 , 84, 86-94	33
111	Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. 2010 , 59, 64-9	19
110	AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD?. 2010 , 40, 623-35	38
109	The S100B/RAGE Axis in Alzheimer's Disease. 2010 , 2010, 539581	48
108	Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. 2010 , 77, 225-31	49
107	C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. 2010 , 142, 273-8	38
106	Implication of the RAGE-EN-RAGE axis in endometriosis. 2010 , 110, 199-202	16
105	Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apoE-deficient mouse. 2010 , 211, 431-6	47
104	Metabolic disorders associated with obstructive sleep apnea in adults. 2011 , 46, 67-138	24
103	The Roles of S100 Proteins and RAGE in Melanoma. 2011 ,	1
102	Soluble receptor for advanced glycation end products is associated with in-stent restenosis in patients with type 2 diabetes with drug-eluting coronary stents. 2011 , 22, 12-7	6
101	Susceptibility of LDL and its subfractions to glycation. 2011 , 22, 254-61	57
100	Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit. 2011 , 12, 1498-512	12
99	Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease. 2011 , 60, 453-9	40
98	Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients. 2011 , 10, 41	27
97	Advanced glycation end-products accumulation compromises embryonic development and achievement of pregnancy by assisted reproductive technology. 2011 , 26, 604-10	60

96	Receptor for advanced glycation end-products expression in subcutaneous adipose tissue is related to coronary artery disease. 2011 , 164, 529-37	22
95	Studies on Renal Disorders. 2011 ,	3
94	What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children?. 2011 , 14, 1167-72	35
93	An explorative analysis of secretory receptor for advanced glycation endproducts in primary focal segmental glomerulosclerosis. 2012 , 16, 589-95	4
92	Serum pentosidine, an advanced glycation end product, indicates poor outcomes after acute ischemic stroke. 2012 , 21, 386-90	10
91	Association study of AGER gene polymorphism and hypertension in Han Chinese population. 2012 , 498, 311-6	7
90	Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). 2012 , 22, 748-55	20
89	AGE/RAGE as a Mediator of Insulin Resistance or Metabolic Syndrome: Another Aspect of Metabolic Memory?. 2012 ,	
88	An update on advanced glycation endproducts and atherosclerosis. 2012 , 38, 266-74	85
87	Modulation of RAGE isoforms expression in the brain and plasma of rats exposed to transient focal cerebral ischemia. 2012 , 37, 1508-16	13
86	The interaction of amyloid β and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells. 2012 , 32, 141-7	37
85	Decreased endogenous secretory RAGE and increased hsCRP levels in serum are associated with atrial fibrillation in patients undergoing coronary angiography. 2013 , 166, 242-5	9
84	Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients. 2013 , 226, 252-7	25
83	Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of Toll-like receptor 2. 2013 , 62, 478-89	72
82	EGCG-rich green tea extract stimulates sRAGE secretion to inhibit S100A12-RAGE axis through ADAM10-mediated ectodomain shedding of extracellular RAGE in type 2 diabetes. 2013 , 57, 2264-8	22
81	Suppression of Receptor for Advanced Glycation End Products Improves Angiogenic Responses to Ischemia in Diabetic Mouse Hindlimb Ischemia Model. 2013 , 2013, 1-7	3
80	Receptor for advanced glycation end products (RAGE) on iNKT cells mediates lung ischemia-reperfusion injury. 2013 , 13, 2255-67	52
79	The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus. 2013 , 9, 739-49	19

78	Calcitriol treatment increases serum levels of the soluble receptor of advanced glycation end products in hemodialysis patients with secondary hyperparathyroidism. 2013 , 230, 59-66	22
77	Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia. 2014 , 744, 91-7	17
76	Soluble form of receptor for advanced glycation end products is associated with obesity and metabolic syndrome in adolescents. 2014 , 2014, 657607	29
75	Processing Contaminants: Advanced Glycation End Products (AGEs). 2014 , 371-375	1
74	On the significance of new biochemical markers for the diagnosis of premature labour. 2014 , 2014, 251451	8
73	Soluble receptor for advanced glycation end products independently predicts cardiometabolic syndrome in Latino youth. 2014 , 15, 403-7	4
72	Total plasma N ^ε (carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects. 2014 , 52, 139-49	30
71	Circulating soluble RAGE increase after a cerebrovascular event. 2014 , 52, 109-16	9
70	Elevation of high-mobility group box 1 after clinical autologous islet transplantation and its inverse correlation with outcomes. 2014 , 23, 153-65	37
69	Improved Insulin Secretion by Autologous Islet Transplantation, Compared to Oral Antidiabetic Agents, After Distal Pancreatectomy. 2015 , 24, 1615-26	8
68	Effects of methanolic extracts of edible plants on RAGE in high-glucose-induced human endothelial cells. 2015 , 25, 257-66	1
67	Rational modulation of the innate immune system for neuroprotection in ischemic stroke. 2015 , 9, 147	140
66	Age and genetic determinants of variation of circulating levels of the receptor for advanced glycation end products (RAGE) in the general human population. 2015 , 145, 18-25	11
65	Regulation of RAGE splicing by hnRNP A1 and Tra2 ^β 1 and its potential role in AD pathogenesis. 2015 , 133, 187-98	17
64	Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis. 2015 , 24, 675-86	13
63	Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory disease. 2015 , 72, 1-8	62
62	Pathophysiology and Medical Treatment of Carotid Artery Stenosis. 2015 , 24, 158-72	21
61	Update on pre-diabetes: Focus on diagnostic criteria and cardiovascular risk. 2016 , 7, 423-432	19

60	Controlled immobilization of His-tagged proteins for protein-ligand interaction experiments using Ni ²⁺ -NTA layer on glass surfaces. 2015 , 61, 523-39		3
59	Hyperglycemia-associated alterations in cellular signaling and dysregulated mitochondrial bioenergetics in human metabolic disorders. 2016 , 55, 2339-2345		71
58	Blockade of receptor for advanced glycation end products protects against systolic overload-induced heart failure after transverse aortic constriction in mice. 2016 , 791, 535-543		16
57	Soluble receptor for advanced glycation end products mitigates vascular dysfunction in spontaneously hypertensive rats. 2016 , 419, 165-76		12
56	Overexpression of soluble RAGE in mesenchymal stem cells enhances their immunoregulatory potential for cellular therapy in autoimmune arthritis. <i>Scientific Reports</i> , 2016 , 6, 35933	4-9	17
55	Capsaicin, an active ingredient from chilli peppers, attenuates glycative stress and restores sRAGE levels in diabetic rats. 2016 , 21, 406-417		7
54	Dietary consumption of advanced glycation end products and risk of metabolic syndrome. 2016 , 67, 170-6		36
53	HMGB1 as a Key Mediator of Immune Mechanisms in Ischemic Stroke. 2016 , 24, 635-51		60
52	Defective Ribonucleoproteins, Mistakes in RNA Processing, and Diseases. 2017 , 56, 1367-1382		8
51	Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?. 2017 , 26, 1-11		38
50	Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community-Based Cohort. 2017 , 63, 980-989		25
49	AGE-RAGE Stress, Stressors, and Antistressors in Health and Disease. 2018 , 27, 1-12		47
48	Soluble Receptor for Advanced Glycation End Products (sRAGE) is Up-Regulated in Multiple Sclerosis Patients Treated with Interferon β 1a. 2018 , 46, 561-567		9
47	Danger-Associated Molecular Patterns Derived From the Extracellular Matrix Provide Temporal Control of Innate Immunity. 2018 , 66, 213-227		68
46	The advanced glycation end-product N -carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevention. 2018 , 245, 197-208		33
45	Impact of Advanced Glycation End Products on Endothelial Function and Their Potential Link to Atherosclerosis. 2018 ,		2
44	Clinical relevance of cleaved RAGE plasma levels as a biomarker of disease severity and functional outcome in aneurysmal subarachnoid hemorrhage. 2018 , 486, 335-340		6
43	Dietary Recommendations for Patients with Cardiovascular Disease and Diabetes. 2018 ,		

42	Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. 2019 , 20,		28
41	Hemodialysis biomarkers: total advanced glycation end products (AGEs) against oxidized human serum albumin (HSAox). 2019 , 56, 1323-1331		7
40	Soluble RAGE attenuates AngII-induced endothelial hyperpermeability by disrupting HMGB1-mediated crosstalk between AT1R and RAGE. 2019 , 51, 1-15		19
39	Radiological assessment of effectiveness of soluble RAGE in attenuating Angiotensin II-induced LVH mouse model using in vivo 9.4T MRI. <i>Scientific Reports</i> , 2019 , 9, 8475	4.9	3
38	Dynamic oligomerization of hRAGE's transmembrane and cytoplasmic domains within SDS micelles. 2019 , 130, 10-18		2
37	Advanced glycation end products and their ratio to soluble receptor are associated with limitations in physical functioning only in women: results from the CARLA cohort. 2019 , 19, 299		5
36	Advanced Glycation End Products Stimulate Angiotensinogen Production in Renal Proximal Tubular Cells. 2019 , 357, 57-66		12
35	Soluble RAGEs and cardiovascular risk factors in adult offspring of patients with premature coronary heart disease. 2020 , 29, 87-94		0
34	Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness. <i>Hypertension Research</i> , 2020 , 43, 111-120	4.7	8
33	Association of rs2070600 in advanced glycosylation end-product specific receptor with prognosis of heart failure. 2020 , 7, 3561		3
32	AGE-RAGE Axis in the Pathophysiology of Chronic Lower Limb Ischemia and a Novel Strategy for Its Treatment. 2020 , 29, 156-167		6
31	The Impact of Advanced Glycation End-Products (AGEs) on Proliferation and Apoptosis of Primary Stem Cells: A Systematic Review. <i>Stem Cells International</i> , 2020 , 2020, 8886612	5	4
30	Methylglyoxal and soluble RAGE in type 2 diabetes mellitus: Association with oxidative stress. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020 , 19, 515-521	2.5	3
29	miR-21-3p regulates AGE/RAGE signalling and improves diabetic atherosclerosis. <i>Cell Biochemistry and Function</i> , 2020 , 38, 965-975	4.2	5
28	Soluble receptor for advanced glycation end-products promotes angiogenesis through activation of STAT3 in myocardial ischemia/reperfusion injury. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2020 , 25, 341-353	5.4	10
27	Molecular and Cellular Mechanisms Responsible for Beneficial Effects of Mesenchymal Stem Cell-Derived Product "Exo-d-MAPPS" in Attenuation of Chronic Airway Inflammation. <i>Analytical Cellular Pathology</i> , 2020 , 2020, 3153891	3.4	16
26	The AGE-RAGE Axis and RAGE Genetics in Chronic Obstructive Pulmonary Disease. <i>Clinical Reviews in Allergy and Immunology</i> , 2021 , 60, 244-258	12.3	7
25	Glycation reaction and the role of the receptor for advanced glycation end-products in immunity and social behavior. <i>Glycoconjugate Journal</i> , 2021 , 38, 303-310	3	8

24	Serum biomarkers, skin autofluorescence and other methods. Which parameter better illustrates the relationship between advanced glycation end products and arterial stiffness in the general population?. <i>Hypertension Research</i> , 2021 , 44, 518-527	4.7	6
23	Biomarkers of Senescence during Aging as Possible Warnings to Use Preventive Measures. <i>Current Medicinal Chemistry</i> , 2021 , 28, 1471-1488	4.3	4
22	Advanced Glycation End Products: New Clinical and Molecular Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	2
21	Statins: Neurobiological underpinnings and mechanisms in mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 128, 693-708	9	3
20	Diyabetik Makula Hemi ile Diyet İeri Glikasyon Son Hleri (AGEs) ve Oksidatif Stres Arasındaki İinin Deİrlendirilmesi. <i>SaĐ Akademi Kastamonu</i> , 1-2	0.2	0
19	Meta-analysis of RAGE gene polymorphism and coronary heart disease risk. <i>PLoS ONE</i> , 2012 , 7, e50790	3.7	16
18	Association of four genetic polymorphisms of AGER and its circulating forms with coronary artery disease: a meta-analysis. <i>PLoS ONE</i> , 2013 , 8, e70834	3.7	11
17	Serum soluble receptor of advanced glycation end products and risk of metabolic syndrome in Egyptian obese women. <i>EXCLI Journal</i> , 2017 , 16, 973-980	2.4	6
16	Advanced glycation end products and risk of hypertension in Iranian adults: Tehran lipid and glucose study. <i>Journal of Research in Medical Sciences</i> , 2018 , 23, 43	1.6	3
15	Soluble Receptor for Glycation End-products Concentration Increases Following the Treatment of Severe Diabetic Ketoacidosis. <i>JCRPE Journal of Clinical Research in Pediatric Endocrinology</i> , 2020 , 12, 160-167	1.0	3
14	Glycaemic control in type 2 diabetic patients with chronic kidney disease: the impacts on enzymatic antioxidants and soluble RAGE. <i>PeerJ</i> , 2018 , 6, e4421	3.1	5
13	Characterisation of the interaction of neuropilin-1 with heparin and a heparan sulfate mimetic library of heparin-derived sugars. <i>PeerJ</i> , 2014 , 2, e461	3.1	13
12	Implication of RAGE Polymorphic Variants in COPD Complication and Anti-COPD Therapeutic Potential of sRAGE. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021 , 1-12	2	1
11	Glycation and Glycosylation in Cardiovascular Remodeling: Focus on Advanced Glycation End Products and O-Linked Glycosylations as Glucose-Related Pathogenetic Factors and Disease Markers. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
10	Cardiovascular Complications in Renal Failure: Implications of Advanced Glycation End Products and Their Receptor RAGE. 2011 , 257-292		
9	The impact of a modified carbohydrate formula, and its constituents, on glycaemic control and inflammatory markers: A nested mechanistic sub-study. <i>Journal of Human Nutrition and Dietetics</i> , 2021 ,	3.1	1
8	Altern messen İes Alterungsprozesses. 2022 , 19-48		
7	Soluble Receptor for Advanced Glycation End Products (sRAGE) Isoforms Predict Changes in Resting Energy Expenditure in Adults with Obesity during Weight Loss.. <i>Current Developments in Nutrition</i> , 2022 , 6, nzac046	0.4	0

6	Protective Effects of the Soluble Receptor for Advanced Glycation End-Products on Pyroptosis during Myocardial Ischemia-Reperfusion.. <i>Oxidative Medicine and Cellular Longevity</i> , 2021 , 2021, 9570971	6.7	2
5	Oxidative stress and soluble receptor for advanced glycation end-products play a role in the pathophysiology of delirium after cardiac surgery. <i>Scientific Reports</i> , 2021 , 11, 23646	4.9	0
4	Anti-Aging Effects of Polyoxometalates on Skin. <i>Applied Sciences (Switzerland)</i> , 2021 , 11, 11948	2.6	0
3	Targeting Scavenger Receptors in Inflammatory Disorders and Oxidative Stress. <i>Antioxidants</i> , 2022 , 11, 936	7.1	0
2	Dysfunctional gene splicing in glucose metabolism may contribute to alzheimer's disease. <i>Chinese Medical Journal</i> , Publish Ahead of Print,	2.9	
1	Association of Edicarbonyls and Advanced Glycation End Products with Insulin Resistance in Non-Diabetic Young Subjects: A Case-Control Study. 2022 , 14, 4929		0